vs
STANDARD BIOTOOLS INC.（LAB）与TEJON RANCH CO（TRC）财务数据对比。点击上方公司名可切换其他公司
TEJON RANCH CO的季度营收约是STANDARD BIOTOOLS INC.的1.1倍（$21.1M vs $19.6M），TEJON RANCH CO净利率更高（7.5% vs -177.4%，领先184.9%），TEJON RANCH CO同比增速更快（17.7% vs -11.5%），过去两年TEJON RANCH CO的营收复合增速更高（68.8% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
特洪牧场公司总部位于加利福尼亚州莱贝克，是加州规模最大的私有土地持有者之一。该公司于1936年完成注册成立，旨在整合管理大片土地的所有权，这片土地由公司创始人爱德华·菲茨杰拉德·比尔在19世纪五六十年代，整合四份墨西哥 grant 得来的地块合并而成。
LAB vs TRC — 直观对比
营收规模更大
TRC
是对方的1.1倍
$19.6M
营收增速更快
TRC
高出29.2%
-11.5%
净利率更高
TRC
高出184.9%
-177.4%
两年增速更快
TRC
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $21.1M |
| 净利润 | $-34.7M | $1.6M |
| 毛利率 | 48.5% | 30.6% |
| 营业利润率 | -168.5% | 10.9% |
| 净利率 | -177.4% | 7.5% |
| 营收同比 | -11.5% | 17.7% |
| 净利润同比 | -28.8% | -64.7% |
| 每股收益（稀释后） | $-0.09 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABTRC
| Q4 25 | — | $21.1M | ||
| Q3 25 | $19.6M | $12.0M | ||
| Q2 25 | $21.8M | $8.3M | ||
| Q1 25 | $40.8M | $8.2M | ||
| Q4 24 | — | $17.9M | ||
| Q3 24 | $22.1M | $10.9M | ||
| Q2 24 | $22.5M | $5.7M | ||
| Q1 24 | $45.5M | $7.4M |
净利润LABTRC
| Q4 25 | — | $1.6M | ||
| Q3 25 | $-34.7M | $1.7M | ||
| Q2 25 | $-33.5M | $-1.7M | ||
| Q1 25 | $-26.0M | $-1.5M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | $-26.9M | $-1.8M | ||
| Q2 24 | $-45.7M | $957.0K | ||
| Q1 24 | $-32.2M | $-914.0K |
毛利率LABTRC
| Q4 25 | — | 30.6% | ||
| Q3 25 | 48.5% | 28.4% | ||
| Q2 25 | 48.8% | 40.9% | ||
| Q1 25 | 48.4% | 15.0% | ||
| Q4 24 | — | 42.9% | ||
| Q3 24 | 54.9% | 22.9% | ||
| Q2 24 | 46.1% | 45.3% | ||
| Q1 24 | 53.1% | 0.3% |
营业利润率LABTRC
| Q4 25 | — | 10.9% | ||
| Q3 25 | -168.5% | -16.9% | ||
| Q2 25 | -118.1% | -48.8% | ||
| Q1 25 | -80.8% | -50.7% | ||
| Q4 24 | — | 11.9% | ||
| Q3 24 | -120.9% | -34.9% | ||
| Q2 24 | -134.5% | -62.4% | ||
| Q1 24 | -132.2% | -53.8% |
净利率LABTRC
| Q4 25 | — | 7.5% | ||
| Q3 25 | -177.4% | 14.0% | ||
| Q2 25 | -153.7% | -20.6% | ||
| Q1 25 | -63.8% | -17.8% | ||
| Q4 24 | — | 25.0% | ||
| Q3 24 | -122.0% | -16.9% | ||
| Q2 24 | -203.3% | 16.8% | ||
| Q1 24 | -70.6% | -12.3% |
每股收益（稀释后）LABTRC
| Q4 25 | — | $0.05 | ||
| Q3 25 | $-0.09 | $0.06 | ||
| Q2 25 | $-0.09 | $-0.06 | ||
| Q1 25 | $-0.07 | $-0.05 | ||
| Q4 24 | — | $0.16 | ||
| Q3 24 | $-0.07 | $-0.07 | ||
| Q2 24 | $-0.12 | $0.04 | ||
| Q1 24 | $-0.27 | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $9.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $475.2M |
| 总资产 | $539.6M | $630.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABTRC
| Q4 25 | — | $9.5M | ||
| Q3 25 | $129.4M | $3.6M | ||
| Q2 25 | $158.6M | $2.5M | ||
| Q1 25 | $150.9M | $12.3M | ||
| Q4 24 | — | $39.3M | ||
| Q3 24 | $210.6M | $27.4M | ||
| Q2 24 | $269.8M | $33.0M | ||
| Q1 24 | $287.1M | $35.6M |
总债务LABTRC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABTRC
| Q4 25 | — | $475.2M | ||
| Q3 25 | $399.7M | $473.2M | ||
| Q2 25 | $424.5M | $471.5M | ||
| Q1 25 | $454.6M | $472.5M | ||
| Q4 24 | — | $473.6M | ||
| Q3 24 | $489.3M | $468.3M | ||
| Q2 24 | $510.3M | $469.2M | ||
| Q1 24 | $577.3M | $467.4M |
总资产LABTRC
| Q4 25 | — | $630.5M | ||
| Q3 25 | $539.6M | $629.6M | ||
| Q2 25 | $557.0M | $618.5M | ||
| Q1 25 | $579.6M | $614.6M | ||
| Q4 24 | — | $608.0M | ||
| Q3 24 | $681.5M | $598.0M | ||
| Q2 24 | $708.7M | $590.8M | ||
| Q1 24 | $777.7M | $581.6M |
负债/权益比LABTRC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $6.1M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | — |
| 自由现金流率自由现金流/营收 | -118.1% | — |
| 资本支出强度资本支出/营收 | 4.5% | — |
| 现金转化率经营现金流/净利润 | — | 3.88× |
| 过去12个月自由现金流最近4个季度 | $-111.1M | — |
8季度趋势，按日历期对齐
经营现金流LABTRC
| Q4 25 | — | $6.1M | ||
| Q3 25 | $-22.2M | $-2.4M | ||
| Q2 25 | $-20.7M | $-381.0K | ||
| Q1 25 | $-30.3M | $-1.3M | ||
| Q4 24 | — | $14.3M | ||
| Q3 24 | $-27.9M | $2.1M | ||
| Q2 24 | $-39.0M | $-1.8M | ||
| Q1 24 | $-62.5M | $777.0K |
自由现金流LABTRC
| Q4 25 | — | — | ||
| Q3 25 | $-23.1M | $-14.6M | ||
| Q2 25 | $-22.6M | $-20.0M | ||
| Q1 25 | $-35.3M | $-18.9M | ||
| Q4 24 | — | $-42.9M | ||
| Q3 24 | $-30.1M | $-16.8M | ||
| Q2 24 | $-41.0M | $-15.8M | ||
| Q1 24 | $-63.3M | $-7.3M |
自由现金流率LABTRC
| Q4 25 | — | — | ||
| Q3 25 | -118.1% | -122.2% | ||
| Q2 25 | -103.6% | -240.6% | ||
| Q1 25 | -86.6% | -230.1% | ||
| Q4 24 | — | -239.3% | ||
| Q3 24 | -136.4% | -155.2% | ||
| Q2 24 | -182.2% | -277.2% | ||
| Q1 24 | -138.9% | -99.0% |
资本支出强度LABTRC
| Q4 25 | — | — | ||
| Q3 25 | 4.5% | 102.3% | ||
| Q2 25 | 8.7% | 236.0% | ||
| Q1 25 | 12.4% | 213.7% | ||
| Q4 24 | — | 319.1% | ||
| Q3 24 | 10.2% | 174.3% | ||
| Q2 24 | 8.6% | 245.5% | ||
| Q1 24 | 1.7% | 109.5% |
现金转化率LABTRC
| Q4 25 | — | 3.88× | ||
| Q3 25 | — | -1.43× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.19× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.88× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
TRC
暂无分部数据
